10-Q: Journey Medical Corporation Reports Mixed Q3 Results Amidst Emrosi Approval

Journey Medical Corporation's Q3 2024 results show a decrease in product revenue, offset by a gain on debt extinguishment and the FDA approval of Emrosi.

Summary

• Journey Medical Corporation reported a net loss of $2.39 million for the three months ended September 30, 2024, compared to a net income of $16.79 million for the same period in 2023.
• Product revenue decreased by 4% to $14.63 million, while total revenue decreased by 58% to $14.63 million due to a significant drop in other revenue.
• Operating expenses increased slightly by 1% to $17.52 million.
• The company recognized a gain on extinguishment of debt of $1.125 million.
• For the nine months ended September 30, 2024, the net loss was $16.19 million, compared to a net loss of $1.71 million for the same period in 2023.
• Total net product revenue for the nine-month period decreased by 4% to $42.51 million.
• The company had $22.5 million in cash and cash equivalents as of September 30, 2024, compared to $27.4 million at the end of 2023.
• The FDA approved Emrosi on November 4, 2024, triggering a $15 million milestone payment to Dr. Reddys Laboratories, Ltd.

Sentiment

Score: 4

Explanation: The document presents mixed results with a significant net loss and declining revenue, but the FDA approval of Emrosi is a positive development. The company's financial position and going concern status are concerning, leading to a negative sentiment overall.

Positives

• Qbrexza net product revenue increased by 29% in Q3 2024, driven by marketing efforts and expanded access.
• The company recognized a gain on extinguishment of debt of $1.125 million.
• The FDA approval of Emrosi is a significant milestone for the company.
• The company recovered a portion of misappropriated cash from a 2021 cybersecurity incident.

Negatives

• Total revenue decreased by 58% in Q3 2024 due to a significant drop in other revenue.
• Accutane net product revenue decreased by 18% in Q3 2024 due to market competition.
• Amzeeq and Zilxi net product revenue combined decreased by 30% in Q3 2024 due to lower unit sales and increased rebates.
• Net loss for the nine months ended September 30, 2024 was $16.19 million, a significant increase from the $1.71 million loss in the same period of 2023.
• The company has recurring losses and substantial doubt exists about its ability to continue as a going concern.

Risks

• The company faces substantial doubt about its ability to continue as a going concern.
• The company is dependent on the successful commercialization of Emrosi and other products.
• The company may need to raise additional capital, which may not be available or may negatively impact the business.
• The company is subject to intense competition, including from generic versions of its products.
• The company relies on third parties for several aspects of its operations.
• The company is subject to risks related to intellectual property protection and cybersecurity.

Future Outlook

The company anticipates initial supply of Emrosi will be available in late first quarter or early second quarter of 2025. The company may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives.

Management Comments

• The company aims to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through its field sales force.
• The company is completing the manufacturing of Emrosi for the U.S. market and anticipates initial supply will be available in late first quarter or early second quarter of 2025.
• The company intends to commercialize Emrosi in the U.S. with its commercial team.

Industry Context

The company operates in the competitive dermatology pharmaceutical market, where new product approvals and generic competition significantly impact revenue. The approval of Emrosi is a positive development, but the company faces challenges in commercializing the product and managing its financial position.

Comparison to Industry Standards

• The decrease in product revenue and the increase in net loss are concerning when compared to industry benchmarks for pharmaceutical companies.
• The company's reliance on a few key products makes it vulnerable to market competition and pricing pressures, similar to other small-cap pharmaceutical companies.
• The company's cash position is relatively low compared to other companies with similar product pipelines, raising concerns about its ability to fund future operations and growth.
• The company's high operating expenses, particularly in selling, general and administrative, are higher than some of its peers, indicating a need for cost management.
• The company's debt levels are also higher than some of its peers, which could limit its financial flexibility.

Related Party Transactions

• The company recorded related party expenses to Fortress of approximately $8,000 and $11,000 for the three-month periods ended September 30, 2024 and 2023, respectively.
• The company recorded related party expenses to Fortress of approximately $26,000 and $47,000 for the nine-month periods ended September 30, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and going concern status.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may benefit from the availability of Emrosi, but may be concerned about the company's financial stability.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• The company will complete the manufacturing of Emrosi for the U.S. market.
• The company will commercialize Emrosi in the U.S. with its commercial team.
• The company will evaluate market conditions and financing alternatives to enhance its capital structure.
• The company will seek to raise capital through debt or equity financings to expand its product portfolio.

Key Dates

Keywords

Journey Medical Corporation, Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, dermatology, pharmaceuticals, FDA approval, financial results, revenue, net loss, clinical trials, milestone payment, SWK Funding LLC, Fortress Biotech